Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04080531 · ClinicalTrials.gov registry record · Phase 4
Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 165
- Enrollment target
NCT04080531 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 165 participants.
The verdict
NCT04080531, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 165 participants
- Enrollment target
Study Summary
This phase IV trial studies how well influenza vaccination works in preventing infections such as influenza in patients with plasma cell disorders. Influenza infections may theoretically support the growth of tumor cells and improving protection against influenza may improve the status of patients' plasma cell disorder. Giving influenza vaccination may reduce influenza-related complications including infections, hospitalizations, and deaths, and improve the status of plasma cell disorders.
Interventions
- BIOLOGICAL Pneumococcal 13-valent Conjugate Vaccine
- BIOLOGICAL Trivalent Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2019-10-18 |
| Est. Completion | 2022-12-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04080531
The ClinicalTrials.gov registry entry for NCT04080531 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pneumococcal 13-valent Conjugate Vaccine is the first listed.
NCT04080531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04080531 about?
NCT04080531 is a clinical study titled "Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders". This phase IV trial studies how well influenza vaccination works in preventing infections such as influenza in patients with plasma cell disorders. Influenza infections may theoretically support the growth of tumor cells and improving protection against influenza may improve the status of patients' ...
What is the current status of trial NCT04080531?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 165 participants. The study started on 2019-10-18. Estimated completion is 2022-12-15.
What interventions are being tested in trial NCT04080531?
The interventions under investigation include: Pneumococcal 13-valent Conjugate Vaccine (BIOLOGICAL), Trivalent Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04080531?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.